Drugs / Y14
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03673111 | Apr 2017 → Feb 2019 | diabetes mellitus, obesity disorder | Imperial College London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673111 ↗ |
| Modality | Peptide | “extended-release peptide YY analogue” PMID 33606914 ↗ Mar 2021 |
| Route | Subcutaneous | “Y14 single dose, subcutaneous” NCT03673111 ↗ |